तुलना करने के लिए मीट्रिक्स | 298380 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध298380पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −179.5x | −18.7x | −0.3x | |
PEG अनुपात | −2.51 | −0.43 | 0.00 | |
क़ीमत/बुक | 24.0x | 2.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 48.0x | 9.0x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 245.7% | 33.5% | 47.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.7% | 5.6% | अनलॉक करें |
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson’s disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.